Novartis set to present Rhapsido data across a range of immune-mediated diseases at EAACI Congress 2026

Novartis will bring data from 10 abstracts to the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, covering Rhapsido (remibrutinib) clinical trial results alongside real-world evidence on patient burden and treatment experience. Among the highlights are two late-breaking oral presentations: one covering the Phase III RemIND trial of Rhapsido in chronic inducible urticaria (CIndU), and another presenting extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy, together providing scientific evidence for its impact across numerous diseases.”

The accepted abstracts spanning the congress are as follows:

Rhapsido (remibrutinib) — chronic spontaneous urticaria and chronic inducible urticaria

Remibrutinib demonstrated superior efficacy versus placebo alongside a favourable safety profile in patients with chronic inducible urticaria in the Phase 3 REMIND study. Oral presentation, June 12, 12:36 to 12:48pm TRT.

Remibrutinib showed sustained efficacy and a favourable safety profile in patients with chronic spontaneous urticaria during the randomised withdrawal period of the Phase 3b REMIXED extension study. Oral presentation, June 12, 12:48 to 1:00pm TRT.

Remibrutinib-driven reductions in B cell biomarkers were found to be associated with complete and sustained response in chronic spontaneous urticaria patients. Flash talk, June 15, 1:12 to 1:19pm TRT.

Rhapsido (remibrutinib) — chronic spontaneous urticaria

REASSERT: a global, prospective, non-interventional, patient-centric study examining the effectiveness, safety, and quality of life outcomes of remibrutinib in patients with chronic spontaneous urticaria. Flash talk, June 14, 6:03 to 6:10pm TRT.

Rhapsido (remibrutinib) — food allergy

Efficacy and safety of remibrutinib in adults with IgE-mediated peanut allergy: findings from a Phase 2 study. Thematic poster session, June 13, 12:00 to 1:00pm TRT.

Dose-response analysis of remibrutinib in oral food challenge outcomes among adults with IgE-mediated peanut allergy. Thematic poster session, June 13, 12:00 to 1:00pm TRT.

Disease-focused research — chronic spontaneous urticaria and chronic inducible urticaria

Urticaria Voices: physician-reported perspectives on chronic urticaria care and its treatment in China. Thematic poster session, June 12, 12:00 to 1:00pm TRT.

---

---

Related Topics and Keywords

EAACI, EAACI Congress 2026, Novartis, Rhapsido